For your safety, everyone is required to wear a mask in Houston Methodist facilities. Find out more >

Showing 1 - 5 of 5 Blood and Lymph Conditions
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

Status: Enrolling

Investigator: Shilpan Shah

Study Coordinator:

Phone:

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of th ... Read more >

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Status: Enrolling

Investigator: Shilpan Shah

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has co ... Read more >

Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator:

Phone:

A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma. ... Read more >

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Status: Enrolling

Investigator: Shilpan Shah

Study Coordinator:

Phone:

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense ho ... Read more >

Sample and Data Collection for Hematologic disorders section, Houston Methodist Cancer Center

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone ... Read more >